Abstract 38P
Background
Patients who reach pathological complete remission (PCR) after neoadjuvant therapy for triple-negative breast cancer (TNBC) have a better overall prognosis and do not require additional adjuvant therapy postoperatively according to current guidelines; however, some patients still have a lower survival rate.
Methods
We identified TNBC patients who completed neoadjuvant therapy and achieved PCR registered in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. We analyzed the relationship between clinicopathological characteristics and overall survival, seeking to explore the high-risk factors for poor prognosis in patients who achieved PCR after neoadjuvant therapy for TNBC.
Results
A total of 1237 TNBC patients without distant metastases completed neoadjuvant therapy and achieved PCR, and their 5-year overall survival rate was 90.78%. We incorporated age, TNM stage (AJCC 7th edition), and presence of lymph node metastasis as variables to construct a multifactorial COX proportional risk model. The results found no statistically significant effect on survival time in stage II patients compared to stage I patients (HR=1.057, 95%CI 0.540-2.069, P=0.872), but statistically significant compared to stage III patients (HR=2.441, 95%CI 1.159-5.144, P=0.019). There was a statistically significant effect on survival time in patients with lymph node metastases compared to those without lymph node metastases (HR=1.913, 95%CI 1.253-2.921, P=0.003); and no statistically significant effect on survival time in patients younger than 40 years compared to those older than 40 years (HR=1.190, 95%CI 0.615-2.302, P= 0.605).
Conclusions
Younger age is not a factor influencing the prognosis of TNBC patients with PCR. For patients with stage III or lymph node metastases, even if PCR is achieved, further adjuvant therapy may be needed to improve prognosis. The type of adjuvant therapy to be used may need to be further confirmed by future prospective clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract